This week, eight biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).

This week, La Jolla Pharmaceutical Company (LJPC) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). In Portfolio Grader’s specific subcategories of Earnings Momentum and Earnings Revisions, LJPC also gets A’s. For more information, get Portfolio Grader’s complete analysis of LJPC stock.

AVEO Pharmaceuticals, Inc. (AVEO) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Aveo Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing cancer therapeutics. Shares of the stock have been trading at an exceptionally rapid pace, up 762.3% from the week prior. For more information, get Portfolio Grader’s complete analysis of AVEO stock.

Incyte Corporation (INCY) earns a B this week, jumping up from last week’s grade of C. Incyte is using its expertise in genomics and medicinal chemistry, as well as molecular, cellular, and in vivo biology to discover and develop novel therapeutics. For more information, get Portfolio Grader’s complete analysis of INCY stock.

This week, Ambit Biosciences Corp.’s (AMBI) ratings are up from a C last week to a B. For more information, get Portfolio Grader’s complete analysis of AMBI stock.

Progenics Pharmaceuticals, Inc. (PGNX) improves from a C to a B rating this week. Progenics Pharmaceuticals develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

Celladon Corporation (CLDN) is seeing ratings go up from a B last week to an A this week. For more information, get Portfolio Grader’s complete analysis of CLDN stock.

Applied Genetic Technologies Corp. (AGTC) boosts its rating from a C to a B this week. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of AGTC stock.

This week, Cerulean Pharma, Inc. (CERU) pushes up from a C to a B rating. Shares of the stock have been changing hands at an unusually rapid pace, up 898.3% from the week prior. For more information, get Portfolio Grader’s complete analysis of CERU stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.